

EMA/HMPC/563195/2024 EMA/HMPC/M/H/0271 Committee on Herbal Medicinal Products (HMPC)

Opinion of the HMPC on a European Union herbal monograph on *Eucalyptus globulus* Labill.; *Eucalyptus polybractea* R.T. Baker; *Eucalyptus smithii* R.T. Baker, aetheroleum

Opinion

The HMPC, in accordance with Article 16h(3) of Directive 2001/83/EC and as set out in the appended assessment report, establishes by a majority of 25 out of 26 votes a revised European Union herbal monograph on *Eucalyptus globulus* Labill.; *Eucalyptus polybractea* R.T. Baker; *Eucalyptus smithii* R.T. Baker, aetheroleum which is set out in Annex I.

The divergent position is appended to this opinion.

The Norwegian HMPC member agrees with the above-mentioned recommendation of the HMPC.

This opinion is forwarded to Member States and Norway, together with its Annex I and appendices.

The revised European Union herbal monograph and assessment report will be published on the European Medicines Agency website. They replace those adopted on 25 March 2014.

Amsterdam, 20 November 2024.



Annex I: European Union herbal monograph (EMA/HMPC/320292/2023)	



Appendix II: Divergent positions

The member of the HMPC mentioned below did not agree with the HMPC's opinion for the following reason:

Ireland does not support the proposed EU herbal monograph for Eucalypti aetheroleum. We do not support the use in children < 12 years as this is not appropriate for self-medication in this population. This is in line with our nationally approved THMPs.

Jackie Masterson, HMPC member from Ireland.

Amsterdam, 20 November 2024.